Catalyst Capital Advisors’s UroGen Pharma URGN Stock Holding History

Catalyst Capital Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-380	Closed	-$19K	–	562
2018 Q1	$19K	Hold	380	–	–	﹤0.01%	318
2017 Q4	$14K	Hold	380	–	–	﹤0.01%	335
2017 Q3	$12K	Hold	380	–	–	﹤0.01%	353
2017 Q2	$7K	Buy	+380	New	+$6.6K	﹤0.01%	426

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Catalyst Capital Advisors's URGN Position: Q2 2018 in Review

Catalyst Capital Advisors sold out of UroGen Pharma (URGN) in Q2 2018, closing a stake of 380 shares — an estimated $19K sold.

Catalyst Capital Advisors first reported a position in URGN in Q2 2017 and held it in 4 quarters. The position peaked at $19K in Q1 2018. 60 funds tracked by Wall St. Rank hold URGN as of Q2 2018.

Catalyst Capital Advisors reported no remaining UroGen Pharma position as of Q2 2018 after selling out during the quarter.
Catalyst Capital Advisors sold 380 UroGen Pharma shares in Q2 2018, an estimated $19K.
Catalyst Capital Advisors first reported a position in UroGen Pharma in Q2 2017 and held it in 4 quarters.
Catalyst Capital Advisors's UroGen Pharma position peaked at $19K in Q1 2018.
60 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2018.

Based on Catalyst Capital Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.